{"id":4292,"date":"2025-03-31T18:12:03","date_gmt":"2025-03-31T18:12:03","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/pimozide-txt\/"},"modified":"2025-03-31T18:12:03","modified_gmt":"2025-03-31T18:12:03","slug":"pimozide-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/pimozide-txt\/","title":{"rendered":"Pimozide.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAntipsychotic

DOSE IN NORMAL RENAL FUNCTION <\/H3>2\u201320 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :461.5<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :99<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <1<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :No data<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :55\u2013150\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start with low dose and increase according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval \u2013 avoid concomitant use with amiodarone, disopyramide and procainamide (risk of ventricular arrhythmias)\n
  • Antibacterials: avoid concomitant use with macrolides and moxifloxacin (increased risk of ventricular arrhythmias)\n
  • Antidepressants: concentration increased by sertraline and possibly paroxetine \u2013 avoid with paroxetine; increased risk of ventricular arrhythmias with maprotiline and tricyclics \u2013 avoid concomitant use; increased plasma level of tricyclics\n
  • Anti-epileptics: antagonises anticonvulsant effect\n
  • Antifungals: avoid concomitant use with imidazoles and triazoles\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine; increased risk of ventricular arrhythmias with mefloquine and quinine \u2013 avoid concomitant use\n
  • Antipsychotics: increased risk of ventricular arrhythmias with phenothiazines \u2013 avoid concomitant use\n
  • Antivirals: concentration increased by amprenavir, atazanavir, efavirenz, indinavir, nelfinavir, ritonavir and saquinavir, increased risk of ventricular arrhythmias \u2013 avoid concomitant useAnxiolytics and hypnotics: increased sedative effectsAprepitant: avoid concomitant use\n
  • Atomoxetine: increased risk of ventricular arrhythmias\n
  • Beta-blockers: increased risk of ventricular arrhythmias with sotalol\n
  • Diuretics: increased risk of ventricular arrhythmias due to hypokalaemiaIvabradine: increased risk of ventricular arrhythmias\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>ECG required before treatment. To be repeated annually.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antipsychotic DOSE IN NORMAL RENAL FUNCTION 2\u201320 mg<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4292","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4292"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4292\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}